BioNTech stellt erste modulare mRNA-Produktionsanlage zur Unterstützung einer skalierbaren Impfstoffproduktion in Afrika vor
16 févr. 2022 05h30 HE
|
BioNTech SE
Entwicklung von schlüsselfertigen modularen Produktionsanlagen als Lösung für eine skalierbare Herstellung von mRNA-basierten Impfstoffen; Anlagen werden von BioNTech eingerichtetTreffen der...
BioNTech introduces first modular mRNA manufacturing facility to promote scalable vaccine production in Africa
16 févr. 2022 05h30 HE
|
BioNTech SE
Developing turnkey solution to enable mRNA-based vaccine production in modular and scalable sites installed by BioNTech Presidents of Ghana, Rwanda, Senegal, the Director-General of the World Health...
Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission
08 févr. 2022 07h30 HE
|
Xanadu Bio
~ Company licenses PACE, a next generation polymeric nanoparticle delivery platform, and options intranasal PACE/Spike mRNA and Spike recombinant protein vaccine boosters for the treatment of...
BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022
24 janv. 2022 15h52 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
16 déc. 2021 07h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety,...
SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
16 déc. 2021 06h00 HE
|
SAB Biotherapeutics, Inc.
FDA laboratory testing confirms SAB-185 neutralizes Omicronand other variants of concern with in vitro pseudovirus model SAB’s targeted, highly potent and fully-human polyclonal antibodies continue...
Clinical Trial Market Size & Share 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
09 nov. 2021 06h00 HE
|
Graphical Research
Pune, India, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The global clinical trial market size is estimated to rise exponentially during the forecast period, as the need for advanced vaccines and drugs to...
BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium
29 oct. 2021 15h44 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases...
Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million
05 août 2021 16h05 HE
|
Fluidigm Corporation
Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. ...
BioNTech gibt Update zu Entwicklungsplänen für nachhaltige Lösungen gegen Infektionskrankheiten auf dem afrikanischen Kontinent
26 juil. 2021 10h00 HE
|
BioNTech SE
BioNTech will den ersten mRNA-basierten Impfstoff zur Malaria-Prävention entwickeln und plant den Start einer klinischen Studie bis Ende 2022 BioNTech prüft nachhaltige Lösungen für...